Expanding access to monoclonal antibody-based products: A global call to action
Monoclonal antibodies (mAbs) are biologic drugs that have had a transformative effect on the treatment of many cancers and autoimmune diseases over the past several decades. Their potential for treating and preventing infectious and neglected diseases is enormous, and several mAbs targeting infectious diseases are licensed. In fact, more than 70 mAb candidates are currently in development for treatment and prevention of COVID-19, including some of IAVI’s own recently identified SARS-CoV-2 antibodies.
